Vanta Bioscience Ltd (VANTABIO) is currently trading at N/A per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Vanta Bioscience Limited specializes in preclinical activities, particularly in toxicology and safety assessments. It operates GLP-certified facilities delivering services to India and globally. Founded in 2016, Vanta Bioscience offers risk assessment for chemical safety, catering to pharmaceuticals, cosmetics, and agrochemicals industries. The company acquired and operates from a preclinical CRO facility in Chennai, acquired from Kemin Industries, providing extensive toxicology services. Vanta Bioscience conducts both in vitro and in vivo toxicology studies under various international regulatory requirements. In 2018-19, Vanta expanded its operations with subsidiaries such as Vanta Clinical Research Limited and Vayam Research Solutions Limited.

Over the past 52 weeks, Vanta Bioscience Ltd has traded between a low of ₹14.71 and a high of ₹29.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Vanta Bioscience Ltd has a market capitalization of approximately 14.64. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Vanta Bioscience Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 133.09 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 14.64 Cr, Vanta Bioscience Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Vanta Bioscience Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Vanta Bioscience Ltd is 133.09. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.